Differential Inhibition of HIV-1 and SIV Envelope-Mediated Cell Fusion by C34 Peptides Derived from the C-Terminal Heptad Repeat of gp41 from Diverse Strains of HIV-1, HIV-2, and SIV
- 25 March 2005
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 48 (8) , 3036-3044
Abstract
The spectrum of inhibition of human (HIV) and simian (SIV) immunodeficiency virus envelope (Env)-mediated cell fusion by C34, a 34 residue peptide corresponding to the C-heptad repeat of gp41 (residues 628−661 of HIV-1 Env), has been examined using a panel of five envelope glycoproteins, three from HIV-1 (LAV, SF162 and 89.6) and two from SIV (mac239 and mac316), and six C34 peptides derived from three strains of HIV-1 (LAV, N CM, and O CM), two strains of HIV-2 (EHO and ALI), and one strain of SIV (African Green Monkey, AGM). A quantitative vaccinia-based reporter gene cell fusion assay was employed. The inhibition data from the panel of 30 C34/envelope glycoprotein combinations, which can be fit to a simple activity relationship with IC50 values spanning a range of over 4 orders of magnitude from 4 nM to 70 μM, permits one to rationalize both the potency and broadness of the inhibitory properties of the C34 peptides in terms of computed interaction free energies between the C34 peptides and the N-helical trimeric coiled-coil of gp41 and the helical propensities of the free C34 peptides. Of particular interest is the finding that the C34 peptide derived from the EHO strain of HIV-2 is a broad spectrum, highly potent inhibitor of Env-mediated cell fusion with IC50 values spanning a very narrow range from only 4 to 25 nM over the entire panel of HIV-1 and SIV envelope glycoproteins tested. This result suggests that C34 from HIV-2 EHO may present a potentially useful therapeutic agent against diverse and/or resistant strains of HIV-1.Keywords
This publication has 27 references indexed in Scilit:
- The Stability of the Intact Envelope Glycoproteins is a Major Determinant of Sensitivity of HIV/SIV to Peptidic Fusion InhibitorsJournal of Molecular Biology, 2004
- The Prefusogenic Intermediate of HIV-1 gp41 Contains Exposed C-peptide RegionsJournal of Biological Chemistry, 2003
- Design and Properties of NCCG-gp41, a Chimeric gp41 Molecule with Nanomolar HIV Fusion Inhibitory ActivityJournal of Biological Chemistry, 2001
- Mechanisms of Viral Membrane Fusion and Its InhibitionAnnual Review of Biochemistry, 2001
- How well does a restrained electrostatic potential (RESP) model perform in calculating conformational energies of organic and biological molecules?Journal of Computational Chemistry, 2000
- Inhibition of HIV-1 entry before gp41 folds into its fusion-active conformationJournal of Molecular Biology, 2000
- Atomic structure of the ectodomain from HIV-1 gp41Nature, 1997
- A Dual-Tropic Primary HIV-1 Isolate That Uses Fusin and the β-Chemokine Receptors CKR-5, CKR-3, and CKR-2b as Fusion CofactorsCell, 1996
- HIV-1 Entry Cofactor: Functional cDNA Cloning of a Seven-Transmembrane, G Protein-Coupled ReceptorScience, 1996
- Quantitative analysis of protein far UV circular dichroism spectra by neural networksProtein Engineering, Design and Selection, 1992